Lazzarin A., Clotet B., Cooper D., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
2.
Dejesus E., Gottlieb MS, Gathe JC Jr, Greenberg ML, Guittari CJ, Zolopa ARSafety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced HIV-infected patients: the below the level of quantification study. Antimicrob Agents Chemother. 2008;52: 4315-4319.
3.
Grinsztejn B. , Nguyen B.-Y, Katlama C., et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet. 2007;369:1261-1269.
4.
Harris M., Larsen G., Montaner JS, et al. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS. 2008;22:1224-1226.
5.
Talbot A., Machouf N., Thomas R., et al. TUPE0112: retrospective analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 12 weeks in a Montreal cohort. Presented at: 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico. Abstract TUPE0112.
6.
Towner W., Klein D., Follansbee S., Yu K., Kerrigan HL, Horberg M.Pilot study of switching enfuvirtide to raltegravir in HIV-1 positive patients well controlled on an enfuvirtide based regimen. Program and abstracts of the 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico. Abstract TUPE0115.
